The European Union's Annex 1 of the GMP Guidelines was finalized and published in August 2022. The guideline provides principles for the design, operation, and control of facilities and processes for sterile medicinal products.
Key Details
- The guideline emphasizes Contamination Control Strategy (CCS) and Quality Risk Management (QRM).
- CCS is defined as an integrated approach to reduce risks of microbial, particulate, and pyrogenic contamination.
- Barrier technologies, especially isolators, are explicitly recommended to reduce human intervention in aseptic processes.
- Robotic solutions are highlighted as a means to minimize manual interventions.
Context
Prior to Annex 1, risk assessments like FMEA were commonly used for manufacturing steps. Isolators provide a fully closed physical separation, offering a higher Sterility Assurance Level (SAL) compared to RABS.
"Section 2.1 of Annex 1 states that manufacturers should consider using appropriate technologies like RABS or isolators to protect products from contamination."
Section 8.9 advises using such equipment to reduce critical interventions. Section 4.3 requires justification if alternatives to RABS or isolators are used.
Conclusion
Annex 1 strengthens the role of isolator technology as the preferred background environment for sterile manufacturing, with justification needed for alternative approaches.